Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predictors of these CoRs could provide insight into vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen-Nissen, Erica, Fiore-Gartland, Andrew, Ballweber Fleming, Lamar, Carpp, Lindsay N., Naidoo, Anneta F., Harper, Michael S., Voillet, Valentin, Grunenberg, Nicole, Laher, Fatima, Innes, Craig, Bekker, Linda-Gail, Kublin, James G., Huang, Ying, Ferrari, Guido, Tomaras, Georgia D., Gray, Glenda, Gilbert, Peter B., McElrath, M. Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959397/
https://www.ncbi.nlm.nih.gov/pubmed/33720973
http://dx.doi.org/10.1371/journal.ppat.1009363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959397/
https://www.ncbi.nlm.nih.gov/pubmed/33720973
http://dx.doi.org/10.1371/journal.ppat.1009363

Ejemplares similares